Please login to the form below

Not currently logged in
Email:
Password:

Ex-BMS exec jumps to Gilead to lead research group

Gilead appoints Michael Quigley to lead research team

A former Bristol-Myers Squibb executive has jumped ship to Gilead, where he will head up the company’s research biology group.

Michael QuigleyMichael Quigley (pictured left) joins Gilead from BMS, where he most recently served as vice president and head of the company’s Tumour Microenvironment Modulation Thematic Research Center and site head of the Redwood City, California location.

At BMS, Quigley held responsibility for setting the strategy for the company’s oncology discovery portfolio and business development activities. He also oversaw target identification, validation and preclinical development of large and small molecule therapies.

Gilead has also simultaneously announced the promotion of Linda Higgins, who has recently taken on the role of senior vice president and head of external innovation.

Linda HigginsHiggins (pictured right) joined Gilead in 2010 to lead an expansion of the company’s biology organisation. That included the expansion of the company’s biologics and biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.

Under her leadership, Gilead’s biology organisation supported the discovery and development of eight marketed products and the development of more than 30 compounds into development.

“We are very pleased to welcome Mike to Gilead and Linda to her new role, as we seek to build and scale our access to scientific innovation, both internally and externally,” commented William Lee. “These appointments strengthen our research discovery organisation and will help position us to reach our ambitious goal of bringing 10 new transformative therapies to patients over the next 10 years.”

Article by
Lucy Parsons

21st February 2020

From: Research

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...